Developer docs
API playgroundTry for free, no card

Search company profiles

Exopharm

Full company profile

uuid003vodt

Namestring
Exopharm
Websiteurl
exopharm.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Exopharm is a clinical-stage biotechnology company headquartered in Melbourne, Australia, developing exosome-based therapeutics and diagnostics for human regenerative medicine. Founded in 2013 by Dr. Ian Dixon, the company is publicly listed on the Australian Securities Exchange under the ticker EX1 and employs between 11 and 50 people. Exopharm operates in the emerging exosome technologies sector, which is projected to reach $0.3 billion in market size by 2030 at a 28.0% compound annual growth rate.

The company's core technology centers on exosomes — small extracellular vesicles — as a platform for both therapeutic and diagnostic product development. Exopharm targets biotechnology and pharmaceutical companies working on exosome-based products, addressing commercialization challenges in a market where no FDA-approved exosome products currently exist. The company's value proposition is enabling the development of exosome-based therapeutic and diagnostic products aligned with personalized medicine needs.

Exopharm's revenue model and pricing structures are not publicly disclosed in available sources, consistent with a pre-commercial clinical-stage profile. Broader industry strategic partnerships and acquisitions involving exosome-based therapeutics and diagnostics are estimated at approximately $1 billion, signaling significant capital deployment in the sector. At the time of data collection, the company's public website was returning a default cPanel server configuration page, suggesting a possible lapse in digital operations or hosting configuration that potential investors and partners should verify.

Short descriptiontext

Exopharm is a Melbourne-based, ASX-listed clinical-stage biotechnology company founded in 2013, developing exosome-based therapeutics and diagnostics for regenerative medicine applications targeting biotechnology and pharmaceutical companies.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
exosome therapeutics, regenerative medicine, cell-free therapy, exosome diagnostics, biopharmaceutical development
Industry2 codes
PRIMARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Exosome Therapeutics
Social media profiles3 records
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Exopharm develops exosome-based therapeutic and diagnostic products for human regenerative medicine applications. The company leverages proprietary exosome technologies to create cell-free therapies and diagnostics targeting the biotechnology and pharmaceutical industry. The offering addresses commercialization and regulatory challenges in an emerging market with no FDA-approved exosome products to date.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Exosome-Based Therapeutics
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing exosome-based therapeutics (notably CAP-1002 and its exosome program, StealthX). Closely comparable to Exopharm in modality, stage, and therapeutic focus on regenerative exosome medicines.

TypeDirect peer
Description

Clinical-stage exosome therapeutics company developing stem cell-derived exosome products for regenerative and aesthetic medicine. Directly comparable to Exopharm in exosome modality and therapeutic focus.

TypeDirect peer
Description

Australia-based clinical-stage regenerative medicine company developing cell-based and exosome-related therapies. Closely comparable to Exopharm in geography, size, and regenerative medicine focus.

TypeDirect peer
Description

UK-based clinical-stage company engineering exosome therapeutics for rare diseases and CNS indications. Directly comparable to Exopharm in modality and stage, with overlapping target indications in regenerative medicine.

5Cynata Therapeutics
TypeDirect peer
Description

ASX-listed (CYP) clinical-stage regenerative medicine company developing stem cell-derived therapeutics. Comparable to Exopharm as a small-cap ASX-listed regenerative medicine peer using biologic-based approaches.

TypeBroad incumbent
Description

ASX-listed (MSB) clinical-stage regenerative medicine company with approved and late-stage cell therapy products. Comparable to Exopharm as a fellow ASX-listed regenerative medicine biotech pursuing cell-based and biologic therapies.

TypeRegional player
Description

UK-listed clinical-stage regenerative medicine company developing stem cell therapies for stroke and retinal disease. Comparable to Exopharm in modality (regenerative biologics) and clinical-stage profile, but in a different geography.

8Codiak BioSciences
TypeDirect peer
Description

Was a clinical-stage developer of engineered exosome therapeutics (engEx platform) for oncology and rare diseases; operates in the same exosome therapeutic modality as Exopharm even though the company has undergone restructuring.

TypeOthers
Description

Major supplier of cell culture and regenerative medicine research tools, including exosome-related reagents. Adjacent ecosystem participant to Exopharm, enabling exosome research but not a direct therapeutic competitor.

TypeEmerging player
Description

Clinical-stage biotech developing exosome-based therapeutics, including engineered extracellular vesicles for inflammatory and rare diseases. Comparable to Exopharm in modality with a similar therapeutic focus on biologics delivery via exosomes.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Exopharm

Exosome Therapeuticsexopharm.com

Exopharm is a Melbourne-based, ASX-listed clinical-stage biotechnology company founded in 2013, developing exosome-based therapeutics and diagnostics for regenerative medicine applications targeting biotechnology and pharmaceutical companies.

What Exopharm does

Exopharm is a clinical-stage biotechnology company headquartered in Melbourne, Australia, developing exosome-based therapeutics and diagnostics for human regenerative medicine. Founded in 2013 by Dr. Ian Dixon, the company is publicly listed on the Australian Securities Exchange under the ticker EX1 and employs between 11 and 50 people. Exopharm operates in the emerging exosome technologies sector, which is projected to reach $0.3 billion in market size by 2030 at a 28.0% compound annual growth rate.

The company's core technology centers on exosomes — small extracellular vesicles — as a platform for both therapeutic and diagnostic product development. Exopharm targets biotechnology and pharmaceutical companies working on exosome-based products, addressing commercialization challenges in a market where no FDA-approved exosome products currently exist. The company's value proposition is enabling the development of exosome-based therapeutic and diagnostic products aligned with personalized medicine needs.

Exopharm's revenue model and pricing structures are not publicly disclosed in available sources, consistent with a pre-commercial clinical-stage profile. Broader industry strategic partnerships and acquisitions involving exosome-based therapeutics and diagnostics are estimated at approximately $1 billion, signaling significant capital deployment in the sector. At the time of data collection, the company's public website was returning a default cPanel server configuration page, suggesting a possible lapse in digital operations or hosting configuration that potential investors and partners should verify.

Exopharm firmographics

Firmographics
Name
Exopharm
Website
https://exopharm.com
Company type
Private
Founded year
2013
Headcount range
11–50 employees
Short description
Exopharm is a Melbourne-based, ASX-listed clinical-stage biotechnology company founded in 2013, developing exosome-based therapeutics and diagnostics for regenerative medicine applications targeting biotechnology and pharmaceutical companies.
Ownership category
akta.pro rank

Exopharm industry classification

Industry
Product category
Exosome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAMANAE
Exosome & Extracellular Vesicle (EV) Therapeutics
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Exosome therapeutics
  • Regenerative medicine
  • Cell-free therapy
  • Exosome diagnostics
  • Biopharmaceutical development

Where Exopharm is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Markets served

Exopharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Exopharm product offering

Product offering

Core offering

Exopharm develops exosome-based therapeutic and diagnostic products for human regenerative medicine applications. The company leverages proprietary exosome technologies to create cell-free therapies and diagnostics targeting the biotechnology and pharmaceutical industry. The offering addresses commercialization and regulatory challenges in an emerging market with no FDA-approved exosome products to date.

Differentiator

Problem solved

Functional benefit

Products and services

  • Exosome-Based Therapeutics

Companies that use Exopharm

Customer profile

Segments1 record

Ideal customer profiles1 record

Exopharm technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Exopharm partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Exopharm competitors and assessment

Company assessment

Direct peers

  • Capricor Therapeutics: Clinical-stage biotech developing exosome-based therapeutics (notably CAP-1002 and its exosome program, StealthX). Closely comparable to Exopharm in modality, stage, and therapeutic focus on regenerative exosome medicines.
  • ExoCoBio: Clinical-stage exosome therapeutics company developing stem cell-derived exosome products for regenerative and aesthetic medicine. Directly comparable to Exopharm in exosome modality and therapeutic focus.
  • Regeneus: Australia-based clinical-stage regenerative medicine company developing cell-based and exosome-related therapies. Closely comparable to Exopharm in geography, size, and regenerative medicine focus.
  • Evox Therapeutics: UK-based clinical-stage company engineering exosome therapeutics for rare diseases and CNS indications. Directly comparable to Exopharm in modality and stage, with overlapping target indications in regenerative medicine.
  • Cynata Therapeutics: ASX-listed (CYP) clinical-stage regenerative medicine company developing stem cell-derived therapeutics. Comparable to Exopharm as a small-cap ASX-listed regenerative medicine peer using biologic-based approaches.
  • Codiak BioSciences: Was a clinical-stage developer of engineered exosome therapeutics (engEx platform) for oncology and rare diseases; operates in the same exosome therapeutic modality as Exopharm even though the company has undergone restructuring.

Broad incumbents

  • Mesoblast: ASX-listed (MSB) clinical-stage regenerative medicine company with approved and late-stage cell therapy products. Comparable to Exopharm as a fellow ASX-listed regenerative medicine biotech pursuing cell-based and biologic therapies.

Regional players

  • ReNeuron: UK-listed clinical-stage regenerative medicine company developing stem cell therapies for stroke and retinal disease. Comparable to Exopharm in modality (regenerative biologics) and clinical-stage profile, but in a different geography.

Others

  • Stemcell Technologies: Major supplier of cell culture and regenerative medicine research tools, including exosome-related reagents. Adjacent ecosystem participant to Exopharm, enabling exosome research but not a direct therapeutic competitor.

Emerging players

  • ILIAS Biologics: Clinical-stage biotech developing exosome-based therapeutics, including engineered extracellular vesicles for inflammatory and rare diseases. Comparable to Exopharm in modality with a similar therapeutic focus on biologics delivery via exosomes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Exopharm social profiles

Digital presence

Exopharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Exopharm leadership team

Management profile

Number of profiles

Profiles2 records

Exopharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Exopharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exopharm

What does Exopharm do?

Exopharm develops exosome-based therapeutic and diagnostic products for human regenerative medicine applications. The company leverages proprietary exosome technologies to create cell-free therapies and diagnostics targeting the biotechnology and pharmaceutical industry. The offering addresses commercialization and regulatory challenges in an emerging market with no FDA-approved exosome products to date.

When was Exopharm founded?

Exopharm was founded in 2013. It employs 11 to 50 people.

Where is Exopharm based?

Exopharm is headquartered in Melbourne, Australia, in the Oceania region.

Who are Exopharm's main competitors?

Direct peers on record are Capricor Therapeutics, ExoCoBio, Regeneus, Evox Therapeutics, Cynata Therapeutics and Codiak BioSciences. Mesoblast is listed as a broad incumbent. ReNeuron is listed as a regional player. Stemcell Technologies is listed as an others. ILIAS Biologics is listed as an emerging player.

Does Exopharm have an API?

No public API is recorded for Exopharm.

What industry is Exopharm in?

Exopharm's product category is Exosome Therapeutics. Its primary akta.pro industry code is HLAMANAE, Exosome & Extracellular Vesicle (EV) Therapeutics, with a secondary code of HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioinformantExosomes as a Burgeoning New Frontier in Cell-Free TherapeuticsStem cell companies are increasingly shifting focus to exosome therapeutics as a response to the commercialization challenges faced by traditional stem cell therapies. Several companies, including Aegle Therapeutics, Exopharm Ltd, and United Therapeutics, are currently conducting clinical trials for exosome-based treatments, with potential applications in various medical conditions. The rise in exosome research and clinical trials suggests a growing market for these cell-free therapeutics.FinanzwireTryp Therapeutics Completes Acquisition by Exopharm LimitedTryp Therapeutics, Inc. has completed its acquisition by Exopharm Limited in an all-stock transaction that became effective on May 1, 2024. Under the terms of the arrangement, Tryp shareholders will receive 3.616 Exopharm shares for each Tryp share they owned, and Tryp will be delisted from the Canadian Securities Exchange. Following the acquisition, Exopharm will begin trading on the Australian Securities Exchange under the new name "Tryptamine Therapeutics Limited."YahooTryp Therapeutics and Exopharm Limited Announce Completion of Plan of ArrangementTryp Therapeutics, Inc. and Exopharm Limited have completed a plan of arrangement effective May 1, 2024, which resulted in Exopharm acquiring Tryp through an all-stock transaction. Each holder of Tryp Shares will receive 3.616 Exopharm Shares, and this completion will lead to the de-listing of Tryp Shares from the Canadian Securities Exchange and the OTCQB Venture Market. Following the acquisition, Exopharm Shares are expected to start trading on the Australian Securities Exchange under a new name on or around May 15, 2024.EuropaWireSmart exosomes from an Australian technology leaderExopharm, founded by Dr Ian Dixon in 2013, marks its 10-year anniversary with a granted US patent for its LEAP exosome manufacturing technology and successful first-in-human trials. The company plans to release pipeline product details later in 2022 and aims to engage more industry experts in 2022.PR NewswireExopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services AgreementExopharm Limited has signed a Master Collaborative Services Agreement with Astellas Institute for Regenerative Medicine (AIRM), a subsidiary of Astellas Pharma Inc., to validate Exopharm's exosome manufacturing technology platforms (LEAP, LOAD, and EVPS). AIRM will pay Exopharm fees of up to US$481,000 over approximately 15 months starting in March 2022, with initial laboratory work at Exopharm's Melbourne facilities followed by technology transfer to AIRM's facilities in Massachusetts. This marks Exopharm's first collaboration services agreement with a major pharmaceutical company, representing a strategic milestone that could serve as the foundation for broader drug development partnerships.BioSpaceExopharm Gains US Patent Enabling Commercial Production of Exosome MedicinesExopharm Limited was granted US patent US 11202805 for its LEAP exosome purification technology, enabling large-scale commercial production of exosomes. The company is seeking partners and licensees, with the patent already granted in Russia and pursued in 10 other jurisdictions.PR NewswireExopharm Gains US Patent Enabling Commercial Production of Exosome MedicinesThe US Patent and Trademark Office has granted Exopharm Limited US patent US 11202805 for its LEAP™ exosome purification technology, enabling large-scale, clinical-grade commercial production of exosomes for the emerging field of exosome medicines. The patent positions Exopharm as a potential global leader in exosome manufacturing and the company is actively seeking partners and licensees, with LEAP™ targeting industry standard status. Exopharm is also developing its own pipeline of exosome medicines while pursuing patent protection in 10 additional global jurisdictions.BioWorldExopharm enters clinic with exosome therapy that could disrupt stem cell therapiesExopharm Ltd. founder and CEO Ian Dixon said stem cell therapy has failed to deliver on its promises. He believes exosomes, the extracellular vesicles released by stem cells, could disrupt the regenerative medicine space. The company is entering the clinic with this therapy.PR NewswireStem Cell Exosomes Market, 2022Research and Markets has released a 134-page market report titled "The Market for Stem Cell Exosomes" analyzing the rapidly growing exosome industry, covering therapeutics, diagnostics, research tools, consumer care products, and manufacturing technologies through 2022. The report highlights significant market momentum, noting that exosome publications grew from 76 articles in 2006 to over 4,400 today, with substantial venture capital flowing into the sector, including Codiak Biosciences raising over $156 million across multiple rounds and Exosome Diagnostics securing $90 million in combined Series B and C funding. Key industry activity includes Lonza's strategic acquisitions of HansaBioMed Life Sciences and investment in Exosomics, as well as partnerships such as RoosterBio and Exopharm collaborating on large-scale clinical-grade exosome manufacturing.BioinformantExopharm to commercialize exosomes for clinical trialsExopharm, an Australian biotech, announced investment to commercialize exosomes for clinical trials. The company plans to become public later in 2017 and target Japan and the USA markets. It aims to produce exomeres at low cost using its LEAP purification technology.